Document is current
Any future updates will be listed below
-
Authors
Chappell, Mark C.
Schaich, Christopher L.
Busse, Laurence W.
Martin, Greg S.
Sevransky, Jonathan E.
Hinson, Jeremiah K.
Khanna, Ashish K.
,
- License Information
-
More Information
Article History
Received: 20 August 2024
Accepted: 3 October 2024
First Online: 14 October 2024
Declarations
:
: The current study was reviewed and approved in April of 2021 with a waiver of consent by the Wake Forest University School of Medicine institutional review board (00073908) and all procedures were followed in accordance with local ethics standards and the Helsinki Declaration of 1975.
: AKK has previously received consulting fees from La Jolla Pharma, including grant funding for the ATHOS3 trial. He has also previously received consulting fees from Innoviva Therapeutics and Viatris Pharmaceuticals. The other authors declare that there are no competing financial interests in the work described in the present study.
